BCY Pharm

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines called Bicycles, which are short, synthetic peptides constrained by a small molecule scaffold into two loops. These molecules combine the high affinity and specificity of antibodies with the small size and pharmacokinetic properties of small molecules. The company's primary focus is on oncology, utilizing its platform to create Bicycle Toxin Conjugates (BTCs), Bicycle Tumor-Targeted Immune Cell Agonists (TICAs), and radiopharmaceuticals. Their lead programs, including BT5528 and BT8009, are currently in mid-stage clinical trials for various solid tumor indications.